Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 8/20 | 0.35 |
| ▸ | BIRC3 | Q13489 | 6/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 6/20 | 0.35 |
| ▸ | BIRC8 | Q96P09 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26842731 | 0.88 | TACR1 (0.41) | TACR1CFDDPP8DPP7XIAP | |
| SCHEMBL24666300 | 0.88 | CFD (0.35) | CFDXIAPBIRC3BIRC2BIRC8 | |
| SCHEMBL29230621 | 0.88 | CFD (0.35) | CFDXIAPBIRC3BIRC2BIRC8 | |
| SCHEMBL26833084 | 0.86 | CFD (0.41) | TACR1CFDDPP8DPP7XIAP | |
| SCHEMBL24666515 | 0.85 | TACR1 (0.41) | TACR1CFDDPP8DPP7XIAP | |
| SCHEMBL24666624 | 0.81 | TACR1 (0.46) | TACR1CFDDPP8DPP7F2 | |
| SCHEMBL24666612 | 0.80 | TACR1 (0.46) | TACR1CFDDPP8DPP7XIAP | |
| SCHEMBL24666613 | 0.80 | TACR1 (0.46) | TACR1CFDDPP8DPP7F2 | |
| SCHEMBL26842786 | 0.80 | TACR1 (0.40) | TACR1CFDDPP8DPP7XIAP | |
| SCHEMBL26842776 | 0.79 | TACR1 (0.41) | TACR1CFDDPP8DPP7F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022198196-A1 | INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |